Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label multicenter study of SCTB39G in advanced malignant solid tumors
CTR20252604Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Aug 2025
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB39G in Nonhematologic neoplasms, sponsored by Sinocelltech Group Limited. Started Aug 2025; status: active.
02
Drugs
SCTB39G
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252604.